Listing standards Anatomy of a Successful 2026 Listing: City Therapeutics and the New Float Rules
With Nasdaq and NYSE American now counting only shares sold in the offering toward float tests, Andy Altahawi examines why the City Therapeutics IPO cleared the 2026 bar and what it teaches issuers.
